Sustained cellular immunity in adults recovered from mild COVID‐19 by Rank, Andreas et al.

COMMUN I C A T I ON TO TH E E D I T O R
Sustained cellular immunity in adults recovered from
mild COVID-19
Andreas Rank1 | Phillip Löhr1 | Reinhard Hoffmann2 | Alanna Ebigbo3 |
Stefanie Grützner4 | Christoph Schmid1 | Rainer Claus1
1Hematology and Oncology, Medical Faculty,
University of Augsburg, Augsburg, Germany
2Institute for Laboratory Medicine and
Microbiology, Medical Faculty, University of
Augsburg, Augsburg, Germany
3Department of Gastroenterology and
Infectious Diseases, Medical Faculty,
University of Augsburg, Augsburg, Germany
4Institute for Transfusion Medicine and
Haemostasis, Medical Faculty, University of
Augsburg, Augsburg, Germany
Correspondence
Rainer Claus, Hematology and Oncology,
Medical Faculty, University of Augsburg,
Stenglinstrasse 2, 86156 Augsburg, Germany.
Email: rainer.claus@uk-augsburg.de
Abstract
Transient lymphocytopenia is frequently observed in acute phase of coronavirus
disease 2019 (COVID-19). It remains a concern whether impairment of cellular immu-
nity may be retained after COVID-19. Here, we demonstrate by extensive lympho-
cyte profiling in 44 adults after mild COVID-19 that cellular immunity is not
fundamentally altered in convalescent patients. Except for increased activated CD8+
lymphocytes, total counts of B, T, and NK cells and their subsets did not differ signifi-
cantly between patients after COVID-19 and healthy controls after a median of
27 days (range 13–45) suggesting no residual cellular immune deficiency after
recovery from mild COVID-19.
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1 | INTRODUCTION
Approximately 20% of patients with coronavirus disease 2019
(COVID-19) have a severe or critical disease with respiratory
or multi-organ dysfunction and a high mortality rate. A total of
80% of patients present with mild COVID-19 or non-severe
pneumonia according to the World Health Organization (WHO).
While pulmonary manifestations dominate the disease phenotype
in most severe cases,1 extent and consequences of impairment of
other organ systems including the cellular immunity2 with subse-
quent susceptibility to secondary infections are less clear to date.
Transient lymphocytopenia is a common finding in COVID-19
and closely related viral diseases by other Coronavirinae, such as
SARS and MERS.3,4 In contrast, lymphocytopenia is generally
rare in most other viral diseases and has been reported for only
few other viruses in the early phase of infection such as the
avian influenza virus H5N1, the respiratory syncytial virus, or
the swine foot-and-mouth disease virus.5–7 Prolonged impaired
cellular immunity following COVID-19 has been a concern based
on observations from the measle virus disease where decrease
of lymphocytes leads to suppression of immune response and
enhanced overall childhood infectious disease mortality.8,9
In this study, we investigated whether patients who have recov-
ered from COVID-19 retain alterations of their lymphocyte subset
composition accompanied by transient immune suppression rendering
them susceptible to subsequent infections. We focused on adult con-
valescents from mild COVID-19 who constitute the vast majority of
patients affected from SARS-CoV-2.
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2 | PATIENTS AND METHODS
2.1 | Patients
Between April 6 and May 15, 2020, B-, T-, and NK-lymphocyte sub-
sets and SARS-CoV-2 antibody IgG and IgA titers (Euroimmun,
Lübeck, Germany) were analyzed in the peripheral blood from
44 adults recovered from COVID-19 and 44 healthy controls. All con-
valescent COVID-19 patients had been tested positive for
SARS-CoV-2 by local health organizations and were recruited from a
call for volunteers for plasma donation. At the time of study enroll-
ment, each patient had a negative test for SARS-CoV-2 and had not
shown symptoms of COVID-19 for at least 2 weeks. A historical
group of healthy controls was built retrospectively from a cohort of
voluntary blood donors from 2019 (pre-COVID-19 era), balancing age
and gender with the COVID-19 patient group. The study was
approved by the institutional ethical committee. Signed informed con-
sent was obtained from all participants.
F IGURE 1 Flowcytometric gating strategy of lymphocyte types and subsets from a healthy donor included in the study. Lymphocytes were
identified by using forward and side scatter; B lymphocytes were defined by the presence of CD19 and T helper and cytotoxic lymphocytes by
the presence of CD4 and CD8, respectively. Lymphocyte subsets were further divided as described in materials and methods and in Table S2
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2.2 | Sample processing and flow cytometric
analysis
EDTA peripheral blood was collected and processed within a maxi-
mum of 24 h. Blood samples were distributed into seven 50 μL ali-
quots. A total of 10 μL of commercial fluorescein isothiocyanate
(FITC-) and phycoerythrin (PE-) as well as 5 μL of phycoerythrin Texas
red-X (ECD-) and phycoerythrin-cyanin (PC5- and PC7-) labeled anti-
bodies purchased from Beckman Coulter (Brea, California) and Bio-
legend (San Diego, California) were added followed by 15 min
incubation (Table S1). Erythrocyte lysis was conducted by addition of
500 μL VersaLyse (Beckman Coulter, California) for 15 min followed
by centrifugation with 360 g for 5 min. Subsequently, samples were
washed with PBS. After cell staining, lymphocyte subsets were ana-
lyzed by flow cytometry-based immunophenotyping (FC500,
Beckman Coulter, California). Raw data were deposited at http://
flowrepository.org/id/FR-FCM-Z343.
To assure data quality, flow rate, laser power calibration, and
event dispersion of the FC 500 flow cytometer were checked on a
daily basis using Flow-Check Pro Fluorospheres (Beckman Coulter).
Autosetups with Cyto-Comp Cells (Beckman Coulter) were routinely
repeated for the automated compensation matrices. Voltages and
compensation settings of all single channels were tested specifically
with beads for the five-color flow cytometry panel of this study.
For correct identification of lymphocyte subsets, plausibility con-
trols with reference material from healthy donors were used repeat-
edly and identical samples were measured as internal standards on a
regular basis.
2.3 | Gating strategy and analysis
For all lymphocyte subsets, percentages were determined, and abso-
lute numbers were calculated. Absolute leukocyte counts were mea-
sured with Stem-Count (Stem-Kit, Beckman Coulter) using
CD45-FITC. A minimum of 10,000 events per aliquot of each sample
was analyzed. Lymphocytes were identified by forward and side scat-
ter. To divide lymphocytes into different subsets, established stan-
dards and a well-described gating strategy as shown in Figure 1 were
used.10 Detailed information on lymphocyte subset specific immune
phenotypes and on fluorochrome-antibody conjugates are listed in
Table S2. B lymphocytes were identified by the presence of CD19
(CD19-PC7 IM3628) and were further divided into naïve (IgD+ CD27
−; IgD-FITC B30652, CD27-ECD B26603), non-class-switched (NCS)
memory (IgD+ CD27+), class-switched (CS) memory (IgD− CD27+)
and transitional (CD24hi CD38hi; CD24-PE IM1428U, CD38-PC5
A07780) subsets. T lymphocytes defined by positivity for CD8 or
CD4 were subdivided into naïve (CD62L+ CD45RA+), memory T cells
(CD4+ CD45RA− CD45RO+/CD8+ CD45RA− CD45RO+), which
were further divided into central memory (CD62L+ CD45RA−), effec-
tor memory (CD62L− CD45RA−), effector memory RA+ (EMRA)
(CD62L− CD45RA+) and activated memory (HLA-DR+ or CD69+)
cells, and FoxP3+ cells. Furthermore, type 1, 2 and 17 CD4+ T helper
(Th1/Th2/Th17) cells were identified by using antibodies against
CXCR3, CCR4, CCR5, and CCR6. Th1 cells were defined as CD4+
CXCR3+ CCR4− CCR5+ CCR6−, Th2 cells as CD4+ CXCR3− CCR4+
CCR5− CCR6− and Th17 cells as CD4+ CXCR3− CCR4+ CCR5−
CCR6+. Within cytotoxic CD8+ T lymphocytes, activated subsets in
early (CD28+ CD27+), intermediate (CD28− CD27+) and late (CD28−
CD27−) status as well as exhausted (CD279+) and terminal effector
(CD279− CD57+) cells were identified. CD56 T cells were defined as
CD56+ CD3+. NK lymphocytes were detected as CD56+ CD3− cells
and subdivided into three NK subsets (CD56+ CD16+, CD56dim
CD16bright, and CD56bright CD16dim).
Wilcoxon test for associated samples (two-tailed) was used to
detect significant differences of lymphocyte subsets among convales-
cent COVID-19 patients and healthy controls. Pre-defined subgroups
defined by sex, age (> vs. < median years), duration of COVID-19, time
from onset, and end of symptoms of COVID-19 (> vs. < median days)
were analyzed within the cohort of patients recovered from
COVID-19. A p value <0.05 was regarded as statistically significant.
TABLE 1 Demographics and characteristics of convalescents
from COVID-19 and age and sex balanced controls
Characteristics
COVID-19
patients (n = 44)
Controls
(n = 44)
Age (years), median (range) 43 (18–61) 40 (18–61)
Gender, n (%)
Male 31 (70.5) 30 (68)
Female 13 (29.5) 14 (32)
Symptoms during COVID-19, n (%)





Dorsal pain 6 (13.6)
Loss of taste 4 (9.1)
Dyspnoe 3 (6.8)
Diarrhoe 2 (4.5)
Duration of symptoms (days),
median (range)
11 (1–26)
Severity of COVID-19 (according to WHO), n (%)









Time from end of symptoms
to analysis (days), median
(range)
27 (13–45)
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3 | RESULTS
Median age of patients was 43 years (range 18–61), 70% were male.
Basic demographics were well matched between cases and healthy
controls (p = 0.930 for age, p = 0.818 for sex). Convalescent COVID-
19 patients did not exhibit relevant comorbidities and had suffered
from mild COVID-19, defined as uncomplicated upper respiratory
tract viral infection or pneumonia without need for supplemental oxy-
gen according to the interim classification and guidance of the WHO.
The most frequent COVID-19 associated symptoms included fever
>38C, myalgia, cough, headache, and sore throat (Table 1). One
patient had radiographically proven pneumonia. Median symptom
duration was 11 days (range 1–26). Median intervals from disease
onset and end of symptoms to assessment of the immune status were
37 (range 26–51) and 27 (range 13–45) days, respectively.
Serological testing showed positivity for anti-SARS-CoV-2 IgG in
39 of 44 patients (89%) and for anti-SARS-CoV-2 IgA in 36 of
44 patients (82%). In 4/44 patients (9%) neither IgA nor IgG titres
were positive, one patient had IgA but no IgG antibodies, and four
patients had IgG but no IgA antibodies. The total numbers of B lym-
phocytes (median 195/μl [range 61–461] for patients vs. 206/μl
[range 65–770] for controls) and their subsets did not differ signifi-
cantly between both groups (Figure 2, upper panel analyzed data
given as lymphocyte subtype per microliter are available in Table S3).
Similarly, total CD3+ lymphocytes (median 1244/μl [range 661–2243]
vs. 1175/μl [range 475–23,224]), total CD4+ (median 753/μl [range
F IGURE 2 Density distribution of main lymphocyte types and subsets between patients of the control cohort (gray) and the COVID-19
cohort (red) displayed as bean plots. Black bars indicate the median, white ticks indicate individual data points, *p = 0.038, **p = 0.002
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196–1365] vs. 833/μl [range 286–1711]) and CD8+ T cells (median
348/μl [range 107–814] vs. 320/μl [range 75–789]) and ratio of
CD4+/CD8+ T cells (median 2.13 vs. 2.28) were not significantly dif-
ferent between convalescents from COVID-19 and controls. Except
for higher numbers of activated CD8+/HLA-DR+ (p = 0.038) and CD8
+/CD69+ lymphocytes (p = 0.002) in COVID-19 patients, no signifi-
cant differences in any of the T lymphocyte subsets were detectable
(Figure 2, lower panel). Subgroup analyses (including patients' age,
gender, and latency between onset/end of symptoms and time of
analysis) did not reveal associations with the cellular immune status
either.
4 | DISCUSSION
The observation of transient lymphocytopenia in COVID-19 patients
raises the question whether impairment of cellular immune response,
followed by increased susceptibility to secondary infections might con-
stitute a concern for convalescents. In this study, no significant differ-
ences between cell numbers for B, T, and NK lymphocytes and most of
their subsets indicative for acquired immune deficiency could be
detected between patients recovered from mild COVID-19 and compa-
rable healthy controls. The only significant lymphocyte subset deviation
observed in our study was an increased number of activated T cells
(CD8+/HLA-DR+ and CD8+/CD69+) in the patient group. This is most
likely due to the recent SARS-CoV-2 infection per se, and timely nor-
malization of these T cell subsets would be expected. Likewise, no alter-
ations of lymphocyte subsets were found in the pre-planned subgroup
analyses of COVID-19 patients. The finding of retained cellular immu-
nity especially with regard to normal counts of memory and regulatory
T cells is of clinical significance, suggesting that long-term immune defi-
ciency as observed, for example, for measles is unlikely for the large
number of patients who recover from mild COVID-19.
Furthermore, a reliable response of the humoral immune system
after mild COVID-19 was demonstrated in our study. This result is line
with published data of previously reported anti-SARS-CoV-2 antibody
testing.11
Our study has some limitations: the focus of our investigation was
centered on adults recovering from mild COVID-19, as they constitute
the vast majority of patients (approximately 80%) affected by SARS-
CoV-2. Thus, our results might not be transferable to more severe dis-
ease courses, to children or to elderly patients. Furthermore, lymphocyte
counts during acute phase of the disease were not available for the
COVID-19 patient cohort due to the design and recruitment procedure
of the study. However, as intermediate or long-term immunodeficiency
might not be reflected by the extent of transient lymphocytopenia but
rather the prolonged alteration of lymphocyte subsets, we could demon-
strate by extensive immune phenotyping efforts that none of the rele-
vant lymphocyte subpopulations exhibited meaningful differences
indicative for impaired cellular immune response.
In summary, our data provide evidence that mild COVID-19 does
not lead to detectable cellular immune deficiencies that may cause
increased susceptibility for subsequent infections. In a current long-
term follow-up, we are assessing the rate of subsequent infections
and related complications after COVID-19.
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